Cannabis Industry Stakeholders React to Trump DOJ’s Rescheduling Order, New Hearing
The cannabis DOJ rescheduling order is a pivotal development impacting medical cannabis access and research funding. Industry stakeholders have expressed mixed reactions to the new hearing and potential changes. This order could reshape federal…
Medical Marijuana Reclassified: Schedule III Research Expansion Explained
The medical marijuana schedule III research expansion removes significant regulatory barriers, enabling more clinical studies. This change accelerates evidence generation for medical applications. Researchers and clinicians can expect increased…
Get the Facts: How DOJ Easing Restrictions on Medical Marijuana Impacts Kentucky
Kentucky medical marijuana federal enforcement changes are reshaping the state's medical cannabis landscape. The DOJ easing restrictions creates regulatory clarity that may accelerate Kentucky's program development. This impacts clinical practice by…
Trump Administration Ready To Move Ahead On Marijuana Rescheduling
The Trump administration cannabis rescheduling update signals a major shift in federal policy. This change could affect clinical practice by altering prescribing protocols and insurance coverage. Healthcare providers should monitor these developments…
Tilray and Cannabis Stocks Surge Amid Federal Reclassification Talks
Cannabis federal reclassification could expand research opportunities and reduce regulatory barriers. This shift may accelerate development of pharmaceutical-grade cannabis products. Market response shows cannabis stocks soaring amid reclassification…
How Trump’s Psychedelics Executive Order Could Unlock Cannabis Reform
Cannabis regulatory momentum is gaining attention as Trump's psychedelics executive order could influence stalled cannabis reform. Policy frameworks for psychedelics and cannabis often intersect in regulatory pathways. Changes in federal psychedelics…
Feds Sued Over Medicare Cannabis Product Coverage (Newsletter: April 1, 2026)
The medicare cannabis coverage lawsuit challenges federal restrictions on coverage for cannabis products. This legal action could change access for Medicare beneficiaries. It highlights critical issues in federal cannabis policy and healthcare coverage.
White House Schedules Additional 2026 Cannabis Enforcement Policy Meetings
The White House has scheduled more 2026 cannabis enforcement policy meetings to discuss federal regulation updates. These meetings affect patient access and clinician liability regarding cannabis products. Stakeholders should monitor these developments…
DOJ Cannabis Rescheduling Update Requested by Congressman (Newsletter: March 30, 2026)
The DOJ cannabis rescheduling update requested by congressman highlights ongoing federal policy deliberations in 2026. Rescheduling cannabis could transform clinical research and prescribing practices. Clinicians should monitor these regulatory changes…
Rescheduling Cannabis Under the Controlled Substances Act | Regulatory Review
Rescheduling cannabis regulatory impact under the Controlled Substances Act could transform research and clinical practice. Lower scheduling may enable more rigorous trials and standardized product development. This shift is crucial for advancing…